FVIII-CAART

FVIII-CAART is an investigational cell therapy designed as a chimeric autoantibody receptor T (CAAR-T) cell therapy specifically targeting and eliminating B cells that produce pathogenic anti-FVIII antibodies. The drug's primary mechanism is to engineer patient T cells to express a chimeric receptor based on coagulation Factor VIII domains, which selectively binds to and eradicates anti-FVIII antibody-producing B cells. The approach is intended for the treatment of hemophilia A patients who have developed inhibitors (autoantibodies) against infused factor VIII, which significantly complicates management. Unlike standard factor VIII replacement or immune tolerance induction, FVIII-CAART aims to offer a targeted, disease-modifying cellular immunotherapy for patients with inhibitor-complicated hemophilia A. The therapy is in early-stage clinical development.

Brand names

FVIII-CAART

Other names

FVIII-CAART